<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fabry disease: Cardiovascular disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fabry disease: Cardiovascular disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Fabry disease: Cardiovascular disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sherif F Nagueh, MD, FACC, FAHA, FASE</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William J McKenna, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 17, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H23202440"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Fabry disease (MIM 300644, also known as angiokeratoma corporis diffusum, ceramide trihexosidosis, or Anderson-Fabry disease) is an X-linked glycolipid storage disease [<a href="#rid1">1,2</a>]. It is caused by deficient activity of the lysosomal enzyme alpha-galactosidase A, resulting in the accumulation of globotriaosylceramide in lysosomes in multiple cell types throughout the body.</p><p>While males are more severely diseased, most heterozygous females are also affected, though usually at a later age [<a href="#rid3">3-6</a>].</p><p>Clinical manifestations are variable and include cutaneous, corneal, cardiac, renal, and neurologic manifestations. The typical presentation occurs in children who suffer from peripheral neuropathy of the hands and feet, nausea, and abdominal pain. However, diagnosis is frequently missed due to the rarity of the disease. Other characteristic features include reduced sweating and the cutaneous lesions of angiokeratoma corporis  (<a class="graphic graphic_picture graphicRef81624" href="/d/graphic/81624.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef71039" href="/d/graphic/71039.html" rel="external">picture 2</a>), which are vascular papules typically distributed in the inguinal, hip, and periumbilical areas. These become more prominent with age. Manifestations of renal disease include proteinuria and progressive renal insufficiency, which sometimes result in end-stage kidney disease. In adults, there is progressive cardiac, renal, and cerebral involvement (transient ischemic attacks and strokes), which are the major causes of death associated with Fabry disease. (See  <a class="medical medical_review" href="/d/html/7195.html" rel="external">"Fabry disease: Clinical features and diagnosis"</a>.)</p><p>The cardiac features of Fabry disease and the incidence of unexpected Fabry disease in patients with otherwise unexplained left ventricular hypertrophy will be reviewed here. The general clinical manifestations and treatment of Fabry disease are discussed separately. (See  <a class="medical medical_review" href="/d/html/7195.html" rel="external">"Fabry disease: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/7207.html" rel="external">"Fabry disease: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H23202342"><span class="h1">CARDIOVASCULAR MANIFESTATIONS</span></p><p class="headingAnchor" id="H426803274"><span class="h2">Clinical features</span><span class="headingEndMark"> — </span>Cardiovascular manifestations of Fabry disease include left ventricular hypertrophy (LVH), aortic and mitral regurgitation, conduction defects, coronary artery disease, hypertension, and aortic root dilation [<a href="#rid6">6-11</a>]. The right ventricle is also often hypertrophied [<a href="#rid12">12</a>]. Many patients with cardiac involvement are asymptomatic, whereas others present with angina, dyspnea, palpitations, or syncope. Rare patients have advanced heart failure symptoms in the setting of unexplained LVH and generally normal LV ejection fraction (LVEF).</p><p>Although LVH has been detected in some children, cardiovascular signs and symptoms are not usually evident until the third or fourth decade or later in males and approximately a decade later in females [<a href="#rid6">6,13</a>]. While males are more severely diseased, most heterozygous females are also affected, though usually at a later age [<a href="#rid3">3-6</a>]. Life expectancy is reduced by approximately 20 years in untreated males and by approximately 15 years in females compared with the general population [<a href="#rid9">9,14</a>]. It has been hypothesized that females are affected due to inactivation of the normal X-chromosome, though the frequency of disease in females is greater than expected due to X-inactivation alone [<a href="#rid6">6</a>].</p><p>Cardiac manifestations typically accompany other findings of Fabry disease, but they can occasionally occur as the sole manifestation of the disease in patients with the "cardiac variant." As an example, in a series of 139 patients with Fabry disease, while 60 percent have cardiovascular signs and symptoms, only two patients had cardiovascular manifestations without any other signs of Fabry disease [<a href="#rid15">15</a>]. Among patients with Fabry disease, females are more likely to present with the cardiac variant of disease [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H23202538"><span class="h3">Ventricular hypertrophy</span><span class="headingEndMark"> — </span>Unexplained LVH is the hallmark of cardiac disease and is more common and more severe in males [<a href="#rid7">7,8,15,17-19</a>]. Several patterns of LVH and remodeling occur, including concentric, asymmetric, and eccentric hypertrophy  (<a class="graphic graphic_figure graphicRef87847" href="/d/graphic/87847.html" rel="external">figure 1</a>) [<a href="#rid13">13</a>]. Early concentric remodeling progresses to concentric hypertrophy, which is the most common pattern seen [<a href="#rid13">13,20</a>]. Asymmetric septal hypertrophy occurs in approximately 5 percent of cases [<a href="#rid20">20</a>]. In some cases of severe cardiac disease, the septum may appear asymmetrically hypertrophied because the basal posterior wall is thinned due to fibrosis. Dynamic LV outflow tract obstruction is rare (occurring in &lt;1 percent) but has been reported [<a href="#rid17">17,18</a>].</p><p>LVH is likely due to both myocyte hypertrophy and glycolipid deposition. The extent of hypertrophy increases with age and is inversely correlated with renal function and alpha-galactosidase A activity [<a href="#rid15">15</a>].</p><p>LVH is generally diagnosed by echocardiography and is frequently suggested by electrocardiography (ECG). Echocardiography also enables detection of alterations in systolic and diastolic myocardial function that may accompany LVH. Cardiovascular magnetic resonance imaging (CMR) is also helpful in identifying LVH and other features of Fabry heart disease. (See <a class="local">'Cardiac tests'</a> below.)</p><p>Right ventricular hypertrophy and impaired right ventricular function (as assessed by strain rate imaging) are also common [<a href="#rid12">12</a>]. Patients with late gadolinium enhancement of the left ventricle had the most impaired right ventricular function.</p><p class="headingAnchor" id="H265155231"><span class="h3">Myocardial fibrosis</span><span class="headingEndMark"> — </span>Interstitial and replacement myocardial fibrosis (particularly around severely narrowed intraluminal coronary arteries) has been observed on endomyocardial biopsy in patients with cardiac Fabry disease with angina [<a href="#rid21">21</a>]. The distribution of myocardial fibrosis can be identified by late gadolinium enhancement on CMR imaging. (See <a class="local">'Cardiovascular magnetic resonance'</a> below.)</p><p class="headingAnchor" id="H426803494"><span class="h3">Valve disease</span><span class="headingEndMark"> — </span>Patients with Fabry disease frequently have mild thickening of mitral and/or aortic valves [<a href="#rid5">5,19</a>]. Aortic, mitral, and tricuspid regurgitation are common [<a href="#rid5">5,19,22</a>]. However, these are usually mild lesions and patients usually do not need valve surgery.</p><p class="headingAnchor" id="H426803500"><span class="h3">Coronary artery disease</span><span class="headingEndMark"> — </span>Angina occurs frequently in both males and females with Fabry disease and appears to be typically caused by coronary small vessel disease, although epicardial coronary artery disease can occur [<a href="#rid6">6,23</a>]. (See <a class="local">'Myocardial perfusion imaging'</a> below and <a class="local">'Coronary angiography'</a> below.)</p><p>Examination of intramural coronary arteries on endomyocardial biopsy reveals luminal narrowing due to hypertrophy and proliferation of smooth muscle and endothelial cells with glycosphingolipid deposits [<a href="#rid21">21,23</a>]. Severely narrowed intramural coronary arteries are often surrounded by myocardial replacement fibrosis.</p><p class="headingAnchor" id="H497694715"><span class="h3">Arrhythmias and conduction abnormalities</span><span class="headingEndMark"> — </span>Atrial and ventricular arrhythmias occur in patients with Fabry disease [<a href="#rid24">24</a>]. Atrial arrhythmias, including atrial fibrillation, are more common and appear related to age. Non-sustained ventricular tachycardia may be related to LV wall thickness. Conduction abnormalities may be caused glycolipid deposition in the atrioventricular (AV) node, His bundle, and bundle branches [<a href="#rid25">25,26</a>]. The PR interval may be short due to accelerated atrioventricular conduction, particularly in younger patients [<a href="#rid27">27</a>]. Older patients may develop PR prolongation (first degree AV block) [<a href="#rid25">25,28</a>] and bundle branch abnormalities and may progress to advanced AV block, though progression to requiring a pacemaker is uncommon [<a href="#rid24">24,29</a>].</p><p class="headingAnchor" id="H497694753"><span class="h3">Aortic dilation</span><span class="headingEndMark"> — </span>Fabry disease may also cause aortic dilation, particularly in males. In a study of 52 males and 54 females (mean age 42 years) with Fabry disease, aortic dilation at the sinus of Valsalva was identified in 33 percent of males and 6 percent of females [<a href="#rid30">30</a>]. Ascending aortic aneurysms (&gt;1.5 x 21 mm/m<sup>2</sup> x body surface area) were present in 10 percent of males and 2 percent of females. In females, the diameter of the sinus of Valsalva correlated with systolic blood pressure, but in males, there was no correlation between aortic diameter and systolic or diastolic blood pressure. (See <a class="local">'Echocardiogram'</a> below and <a class="local">'Cardiovascular magnetic resonance'</a> below.)</p><p class="headingAnchor" id="H2831906"><span class="h3">Hypertension</span><span class="headingEndMark"> — </span>Hypertension is common in patients with Fabry disease with over one-half developing increased blood pressure after the onset of chronic kidney disease. (See  <a class="medical medical_review" href="/d/html/115165.html" rel="external">"Fabry disease: Kidney manifestations", section on 'Hypertension'</a>.)</p><p>Hypertension is a risk factor for cardiovascular events in Fabry disease patients. (See <a class="local">'Heart failure and other cardiovascular events'</a> below.)</p><p class="headingAnchor" id="H2831899"><span class="h3">Heart failure and other cardiovascular events</span><span class="headingEndMark"> — </span>Cardiovascular events in Fabry disease include heart failure, myocardial infarction, and cardiac death. Among 2869 Fabry Registry patients (1424 males and 1445 females) not treated with enzyme replacement therapy, 5.8 percent of males and 3.7 percent of females experienced cardiovascular events at mean ages of 45 and 54 years, respectively [<a href="#rid10">10</a>]. Heart failure was the most common first cardiovascular event. Hypertension and LVH were risk factors for cardiovascular events. Possible causes of sudden death in Fabry disease include ventricular arrhythmias and bradyarrhythmias [<a href="#rid24">24</a>]. (See <a class="local">'Arrhythmias and conduction abnormalities'</a> above.)</p><p class="headingAnchor" id="H426803267"><span class="h2">Cardiac tests</span></p><p class="headingAnchor" id="H4268807"><span class="h3">Electrocardiogram</span><span class="headingEndMark"> — </span>In patients with Fabry disease, the ECG frequently shows LVH by voltage criteria and/or repolarization abnormalities and the QRS is frequently prolonged, particularly in patients with LV remodeling or LVH by echocardiography [<a href="#rid6">6,11,31</a>]. ST segment and Q wave abnormalities have been reported in the absence of myocardial infarction [<a href="#rid26">26,32</a>]. Conduction abnormalities and arrhythmias may occur as described above. (See <a class="local">'Arrhythmias and conduction abnormalities'</a> above.)</p><p class="headingAnchor" id="H4268878"><span class="h3">Cardiac biomarkers</span><span class="headingEndMark"> — </span>Limited data are available on the prevalence of troponin elevations in patients with Fabry disease. In one series, troponin I was elevated in 6 of 13 patients with Fabry disease and angina and in none of 25 patients with Fabry disease without angina [<a href="#rid23">23</a>].</p><p>A study of 117 patients with Fabry disease found that plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) was frequently elevated, particularly in patients with echocardiographic and/or ECG abnormalities [<a href="#rid33">33</a>]. Age, creatinine, left atrial volume index, the ratio of transmitral peak E velocity to the peak Ea velocity of the lateral wall (E/Ea), and presence of ECG findings were independently associated with log NT-proBNP.</p><p class="headingAnchor" id="H426803254"><span class="h3">Echocardiogram</span><span class="headingEndMark"> — </span>Echocardiography is the most common test to assess cardiac morphology, valve function, and ascending aorta diameter, although there are no pathognomonic echocardiographic features in Fabry disease [<a href="#rid6">6</a>]. Concentric LVH is the most frequent pattern of LV remodeling seen with this disease. The LVEF is usually normal. In contrast, speckle tracking and tissue Doppler measures of systolic and diastolic function are frequently abnormal in patients with Fabry disease [<a href="#rid34">34</a>]. Greater wall thicknesses correlate with lower tissue Doppler imaging velocities [<a href="#rid35">35</a>]. Since speckle tracking and tissue Doppler abnormalities also frequently occur in patients with Fabry disease without LVH, they may aid in detection of patients with early cardiac involvement [<a href="#rid34">34,36</a>].</p><p>Some patients with Fabry disease with advanced cardiac involvement have a thinned basal inferolateral wall with focal hypokinesis and regional reductions in longitudinal strain [<a href="#rid37">37</a>]. The presence of a thinned basal inferolateral LV wall or increased LV Tei index are predictors of increased risk of heart failure and cardiac death [<a href="#rid38">38</a>].</p><p>In one series, 51 patients with Fabry disease and 25 controls underwent tissue Doppler echocardiography to measure peak systolic strain rates (SR) [<a href="#rid39">39</a>]. Patients with Fabry disease without LVH had reduced longitudinal SR but normal radial SR while patients with LVH had reduced longitudinal and radial SR. Patients with LVH who had late gadolinium enhancement on CMR imaging had severely reduced radial and longitudinal function.</p><p>An echocardiographic binary appearance of the myocardium (a thickened hyperechogenic endocardial layer subtended by a hypoechogenic layer) was proposed as a marker of Fabry disease reflecting endomyocardial glycosphingolipids compartmentalization  (<a class="graphic graphic_figure graphicRef55283" href="/d/graphic/55283.html" rel="external">figure 2</a>) [<a href="#rid40">40</a>]. However, subsequent studies found that the binary sign had limited sensitivity (15 to 35 percent) and specificity (73 to 80 percent) for Fabry disease [<a href="#rid41">41-43</a>]. The likelihood of a binary sign is associated with the degree of septal hypertrophy [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H426803774"><span class="h3">Cardiovascular magnetic resonance</span><span class="headingEndMark"> — </span>CMR imaging can identify and quantify LVH (by wall thickness and three-dimensional measurement of LV mass) and ascending aorta size if echocardiographic images are suboptimal or nondiagnostic.</p><p>CMR also enables identification of fibrosis by late gadolinium enhancement (LGE), which is frequently observed in patients with Fabry disease [<a href="#rid37">37,44-46</a>]. Among males with Fabry disease, myocardial fibrosis generally occurs only in those with LVH [<a href="#rid47">47</a>]. In contrast, among females with Fabry disease, myocardial fibrosis can occur without LVH. In Fabry disease, LGE characteristically involves the basal and mid segments of the anterolateral and inferolateral walls and in severe cases may involve the basal third of other LV walls. LGE in Fabry disease usually spares the subendocardium, which helps distinguish it from the pattern seen with myocardial infarction [<a href="#rid48">48</a>]. Focal basal lateral replacement fibrosis detected by CMR is associated with regional impaired longitudinal strain on echocardiography (eg, by speckle-tracking) [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/d/html/5314.html" rel="external">"Clinical utility of cardiovascular magnetic resonance imaging", section on 'Late gadolinium enhancement'</a>.)</p><p class="headingAnchor" id="H4268929"><span class="h3">Myocardial perfusion imaging</span><span class="headingEndMark"> — </span>Stress myocardial perfusion imaging in patients with Fabry disease and angina reveals reversible defects consistent with ischemia, often accompanied by fixed defects [<a href="#rid23">23</a>]. These findings generally occur without significant obstructive coronary disease and appear to be due to small coronary vessel disease with replacement fibrosis surrounding severely stenosed intramural arteries. (See <a class="local">'Coronary artery disease'</a> above.)</p><p class="headingAnchor" id="H4269310"><span class="h3">Coronary angiography</span><span class="headingEndMark"> — </span>Coronary angiography in patients with Fabry disease generally shows no epicardial luminal abnormalities with diffuse slow flow likely caused by small vessel disease [<a href="#rid23">23,49</a>]. (See <a class="local">'Coronary artery disease'</a> above.)</p><p class="headingAnchor" id="H23202350"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H23202597"><span class="h2">When to suspect cardiac Fabry disease</span><span class="headingEndMark"> — </span>Given the availability of enzyme replacement therapy, which may favorably alter the course of the disease as well as the potential risk of progressing to irreversible disease [<a href="#rid50">50-52</a>], it is important to diagnose patients afflicted with Fabry disease as early as possible. Fabry disease should be considered in the differential diagnosis of unexplained left ventricular hypertrophy (LVH; ie, absence of causes such as hypertension and aortic stenosis) or cardiomyopathy, particularly hypertrophic cardiomyopathy (HCM) or restrictive cardiomyopathy, though it can rarely present as a dilated cardiomyopathy  (<a class="graphic graphic_table graphicRef64479" href="/d/graphic/64479.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef74268" href="/d/graphic/74268.html" rel="external">table 2</a>) [<a href="#rid10">10,11,53-57</a>] (see  <a class="medical medical_review" href="/d/html/4943.html" rel="external">"Definition and classification of the cardiomyopathies", section on 'Anatomic and physiologic classification'</a>). Exclusion of Fabry disease is an important step in the evaluation of patients with HCM, as approximately 0.3 to 5 percent have Fabry disease [<a href="#rid18">18,53,58</a>]. The 2009 Heart Failure Society of America practice guideline on genetic evaluation of cardiomyopathy recommended screening for Fabry disease in all males with sporadic or nonautosomal dominant (no male-to-male) transmission of unexplained cardiac hypertrophy [<a href="#rid57">57</a>]. (See  <a class="medical medical_review" href="/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation", section on 'Differential diagnosis'</a>.)</p><p>Although cardiac Fabry disease is generally accompanied by other manifestations of Fabry disease, a cardiac variant of the disease rarely presents with LVH without other obvious disease manifestations [<a href="#rid7">7,17,18,53</a>]. Among patients with Fabry disease, the cardiac variant is more common among females than males. (See  <a class="medical medical_review" href="/d/html/7195.html" rel="external">"Fabry disease: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H78348398"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of cardiac Fabry disease includes other causes of LVH, HCM, restrictive cardiomyopathy, or dilated cardiomyopathy  (<a class="graphic graphic_table graphicRef64479" href="/d/graphic/64479.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef74268" href="/d/graphic/74268.html" rel="external">table 2</a>). Other causes of LVH include aortic stenosis, hypertension, athlete’s heart, and obesity. HCM is defined to include a variety of conditions with increased ventricular wall thickness or mass not caused by pathologic loading conditions. Restrictive cardiomyopathy is characterized by nondilated nonhypertrophied ventricles with impaired filling. Dilated cardiomyopathy is characterized by dilated ventricles and impaired systolic function of one or both ventricles. (See  <a class="medical medical_review" href="/d/html/4943.html" rel="external">"Definition and classification of the cardiomyopathies"</a> and  <a class="medical medical_review" href="/d/html/3516.html" rel="external">"Causes of dilated cardiomyopathy"</a> and  <a class="medical medical_review" href="/d/html/4918.html" rel="external">"Restrictive cardiomyopathies"</a> and  <a class="medical medical_review" href="/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation"</a> and  <a class="medical medical_review" href="/d/html/4948.html" rel="external">"Hypertrophic cardiomyopathy: Clinical manifestations, diagnosis, and evaluation", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/d/html/5330.html" rel="external">"Echocardiographic recognition of cardiomyopathies"</a>.)</p><p>Cardiac amyloidosis is a cause of HCM or restrictive cardiomyopathy that should be distinguished from cardiac Fabry disease. A preliminary report found that a septal apical to basal longitudinal peak systolic strain ration &gt;2.1 differentiated cardiac amyloidosis from other causes of LVH, including Fabry disease [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H78348378"><span class="h2">Confirmatory testing</span><span class="headingEndMark"> — </span>In males with suspected Fabry disease, the diagnosis is generally confirmed by measurement of leukocyte alpha-Gal A activity. However, this assay will identify less than 50 percent of female heterozygotes. In females with suspected Fabry disease (and males with marginal levels of alpha-Gal A activity), genetic testing is recommended. (See  <a class="medical medical_review" href="/d/html/7195.html" rel="external">"Fabry disease: Clinical features and diagnosis", section on 'Establishing the diagnosis'</a>.)</p><p>In patients with the cardiac variant of Fabry disease, plasma, or leukocyte alpha-galactosidase A activity is usually low but detectable [<a href="#rid17">17,18</a>], in contrast to patients with the classic Fabry phenotype who may have undetectable activity [<a href="#rid1">1</a>]. The presence of some alpha-galactosidase A activity may prevent the microvascular accumulation of globotriaosylceramide that is responsible for the classic extracardiac manifestations of the disease [<a href="#rid1">1</a>].</p><p>Endomyocardial biopsy is generally not required but can be helpful in confirming that LVH is associated with glycosphingolipid deposition if the diagnosis is uncertain. Histologic findings include perinuclear vacuoles that stain with periodic acid-Schiff stain and Sudan-Black [<a href="#rid21">21</a>]. Electron microscopy reveals myelin bodies that are single membrane bound vesicles containing concentric lamellar figures. Arterial endothelial and smooth muscle cells and interstitial capillary endothelial cells also contain glycosphingolipid deposits [<a href="#rid21">21,60</a>]. Histologic findings are not pathognomonic since similar histologic findings are seen with <a class="drug drug_general" data-topicid="9247" href="/d/drug information/9247.html" rel="external">chloroquine</a> or <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> toxicity [<a href="#rid11">11,61</a>]. (See  <a class="medical medical_review" href="/d/html/4923.html" rel="external">"Endomyocardial biopsy", section on 'Restrictive cardiomyopathy'</a>.)</p><p class="headingAnchor" id="H3246289370"><span class="h2">Screening family members</span><span class="headingEndMark"> — </span>Screening is suggested for family members of patients diagnosed with Fabry disease, as discussed separately. Early diagnosis of Fabry disease is advocated since enzyme replacement therapy may favorably alter the course of the disease. (See  <a class="medical medical_review" href="/d/html/7195.html" rel="external">"Fabry disease: Clinical features and diagnosis", section on 'Screening family members'</a>.)</p><p class="headingAnchor" id="H497695012"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Patients with Fabry disease with cardiac manifestations should generally receive standard therapies for heart disease, including antianginal medication for angina, standard antiarrhythmic therapy, and guideline-directed therapy for heart failure. In addition, we suggest initiating enzyme replacement therapy (ERT) in patients with Fabry disease with cardiac manifestations, although the impact on cardiovascular outcomes is not known. (See  <a class="medical medical_review" href="/d/html/7207.html" rel="external">"Fabry disease: Treatment and prognosis", section on 'Fabry-specific therapy'</a>.)</p><p class="headingAnchor" id="H2569603843"><span class="h2">Cardiovascular effects</span></p><p class="headingAnchor" id="H497695056"><span class="h3">Angina</span><span class="headingEndMark"> — </span>Patients with Fabry disease frequently complain of angina. Antianginal medications are indicated in patients with angina caused by small vessel disease. Evaluation with stress testing and coronary angiography is indicated in some patients to identify concurrent epicardial coronary artery disease [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/1483.html" rel="external">"Chronic coronary syndrome: Overview of care"</a> and  <a class="medical medical_review" href="/d/html/48.html" rel="external">"Overview of the nonacute management of unstable angina and non-ST-elevation myocardial infarction"</a>.)</p><p class="headingAnchor" id="H497695179"><span class="h3">Arrhythmia and conduction disease</span><span class="headingEndMark"> — </span>Patients with Fabry disease should receive standard therapy for atrial and ventricular arrhythmias. Depending on the frequency of any symptoms, a 48-hour Holter recorder or an event recorder [<a href="#rid62">62</a>] may be considered to detect possible arrhythmias. Permanent pacemaker implantation is occasionally required to treat symptomatic bradycardia and/or advanced conduction system disease. Some patients with advanced cardiomyopathy may require implantable cardioverter-defibrillator placement to prevent sudden cardiac death. (See  <a class="medical medical_review" href="/d/html/941.html" rel="external">"Permanent cardiac pacing: Overview of devices and indications"</a> and  <a class="medical medical_review" href="/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation"</a> and  <a class="medical medical_review" href="/d/html/917.html" rel="external">"Nonsustained ventricular tachycardia: Clinical manifestations, evaluation, and management"</a> and  <a class="medical medical_review" href="/d/html/91077.html" rel="external">"Primary prevention of sudden cardiac death in patients with cardiomyopathy and heart failure with reduced LVEF"</a>.)</p><p class="headingAnchor" id="H497695134"><span class="h3">Asymptomatic left ventricular systolic dysfunction</span><span class="headingEndMark"> — </span>Patients without symptoms with reduced left ventricular ejection fraction should receive an angiotensin converting enzyme inhibitor. A beta blocker is also suggested in such patients, though supporting evidence is limited. (See  <a class="medical medical_review" href="/d/html/3509.html" rel="external">"Management and prognosis of asymptomatic left ventricular systolic dysfunction"</a>.)</p><p class="headingAnchor" id="H2832776"><span class="h3">Hypertension</span><span class="headingEndMark"> — </span>Treatment of hypertension in patients with Fabry disease is discussed separately. (See  <a class="medical medical_review" href="/d/html/7207.html" rel="external">"Fabry disease: Treatment and prognosis", section on 'Fabry-specific therapy'</a>.)</p><p class="headingAnchor" id="H497695019"><span class="h3">Heart failure</span><span class="headingEndMark"> — </span>Patients with Fabry disease with heart failure should receive conventional evidence-based and guideline-directed medical therapy [<a href="#rid63">63-65</a>]. Successful heart transplantation for advanced Fabry cardiac disease has been performed without development of Fabry disease in the graft, likely due to enzyme activity in the graft [<a href="#rid66">66</a>]. (See  <a class="medical medical_review" href="/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction"</a> and  <a class="medical medical_review" href="/d/html/121085.html" rel="external">"Overview of the management of heart failure with reduced ejection fraction in adults"</a>.)</p><p class="headingAnchor" id="H3588473353"><span class="h3">Aortic dilation</span><span class="headingEndMark"> — </span>Given the risk of development of ascending aortic aneurysm described above, patients with Fabry disease should be monitored for progressive ascending aortic dilation, as described separately. In patients with Fabry disease with aortic dilation, we generally follow general guidelines for degenerative thoracic aortic aneurysm surveillance and prophylactic repair. There is scant evidence available to guide management of aortic aneurysm in patients with Fabry disease. (See <a class="local">'Aortic dilation'</a> above and  <a class="medical medical_review" href="/d/html/8189.html" rel="external">"Management of thoracic aortic aneurysm in adults", section on 'Aneurysm surveillance'</a> and  <a class="medical medical_review" href="/d/html/8189.html" rel="external">"Management of thoracic aortic aneurysm in adults", section on 'Degenerative TAA'</a>.)</p><p class="headingAnchor" id="H23202358"><span class="h2">Enzyme replacement therapy</span><span class="headingEndMark"> — </span>Enzyme replacement therapy (ERT) can reduce the deposition of globotriaosylceramide in the myocardium and may reduce LV hypertrophy and improve symptoms. The use of ERT depends on factors that include sex, circulating levels of alpha-Gal-A, and the severity of disease. The indications for treatment and effects of treatment are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7207.html" rel="external">"Fabry disease: Treatment and prognosis", section on 'Fabry-specific therapy'</a>.)</p><p class="headingAnchor" id="H933943571"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/122565.html" rel="external">"Society guideline links: Fabry disease"</a> and  <a class="medical medical_society_guidelines" href="/d/html/115372.html" rel="external">"Society guideline links: Heart failure in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/115416.html" rel="external">"Society guideline links: Cardiomyopathy"</a>.)</p><p class="headingAnchor" id="H23202680"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – Cardiovascular manifestations of Fabry disease include left ventricular hypertrophy (LVH), right ventricular hypertrophy, aortic and mitral regurgitation, arrhythmias, conduction defects, coronary artery disease, hypertension, and aortic root dilation. Many patients with cardiac involvement are asymptomatic, whereas others present with angina, dyspnea, palpitations, syncope, or heart failure. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Manifestations</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ventricular hypertrophy</strong> – Unexplained LVH is the hallmark of Fabry cardiac disease and is more common and more severe in males. (See <a class="local">'Ventricular hypertrophy'</a> above.)</p><p></p><p class="bulletIndent2">LVH is generally diagnosed by echocardiogram and may be suspected on ECG. Cardiovascular magnetic resonance (CMR) imaging can confirm LVH and also enables identification of myocardial fibrosis. (See <a class="local">'Cardiac tests'</a> above.)</p><p></p><p class="bulletIndent2">Fabry disease should be considered in the differential diagnosis of unexplained LVH, particularly hypertrophic cardiomyopathy or restrictive cardiomyopathy, though it can rarely present as a dilated cardiomyopathy  (<a class="graphic graphic_table graphicRef64479" href="/d/graphic/64479.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef74268" href="/d/graphic/74268.html" rel="external">table 2</a>). (See <a class="local">'When to suspect cardiac Fabry disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Coronary artery disease</strong> – Angina occurs frequently in both males and females with Fabry disease and appears to be typically caused by coronary small vessel disease, though epicardial coronary artery disease can occur. (See <a class="local">'Coronary artery disease'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Males</strong> – In males with suspected Fabry disease, the diagnosis is generally confirmed by measurement of leukocyte alpha-Gal A activity. However, this assay will identify less than 50 percent of female heterozygotes. (See <a class="local">'Confirmatory testing'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Females</strong> – In females with suspected Fabry disease (and males with marginal levels of alpha-Gal A activity), genetic testing is recommended. (See <a class="local">'Confirmatory testing'</a> above and  <a class="medical medical_review" href="/d/html/7195.html" rel="external">"Fabry disease: Clinical features and diagnosis", section on 'Establishing the diagnosis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Role of endomyocardial biopsy</strong> – Endomyocardial biopsy is generally not required to diagnose Fabry disease but can be helpful in confirming that LVH is associated with glycosphingolipid deposition if the diagnosis is uncertain. (See <a class="local">'Confirmatory testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment of cardiac complications</strong> – Patients with Fabry disease with cardiac manifestations should generally receive standard therapy to treat heart failure, arrhythmias, and angina. (See <a class="local">'Cardiovascular effects'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Enzyme replacement therapy</strong> – Enzyme replacement therapy (ERT) can reduce the deposition of globotriaosylceramide in the myocardium and may reduce LV hypertrophy and improve symptoms. The use of ERT depends on factors that include sex, circulating levels of alpha-Gal-A, and the severity of disease. The indications for treatment, agents available for use, and effects of treatment are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7207.html" rel="external">"Fabry disease: Treatment and prognosis", section on 'Fabry-specific therapy'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003; 138:338.</a></li><li><a class="nounderline abstract_t">Eng CM, Ashley GA, Burgert TS, et al. Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol Med 1997; 3:174.</a></li><li><a class="nounderline abstract_t">Wang RY, Lelis A, Mirocha J, Wilcox WR. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 2007; 9:34.</a></li><li><a class="nounderline abstract_t">Weidemann F, Niemann M, Sommer C, et al. Interdisciplinary approach towards female patients with Fabry disease. Eur J Clin Invest 2012; 42:455.</a></li><li><a class="nounderline abstract_t">Kampmann C, Baehner F, Whybra C, et al. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 2002; 40:1668.</a></li><li><a class="nounderline abstract_t">O'Mahony C, Elliott P. Anderson-Fabry disease and the heart. Prog Cardiovasc Dis 2010; 52:326.</a></li><li><a class="nounderline abstract_t">Nagueh SF. Fabry disease. Heart 2003; 89:819.</a></li><li><a class="nounderline abstract_t">Kampmann C, Baehner F, Ries M, Beck M. Cardiac involvement in Anderson-Fabry disease. J Am Soc Nephrol 2002; 13 Suppl 2:S147.</a></li><li><a class="nounderline abstract_t">MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38:750.</a></li><li><a class="nounderline abstract_t">Patel MR, Cecchi F, Cizmarik M, et al. Cardiovascular events in patients with fabry disease natural history data from the fabry registry. J Am Coll Cardiol 2011; 57:1093.</a></li><li><a class="nounderline abstract_t">Gambarin FI, Disabella E, Narula J, et al. When should cardiologists suspect Anderson-Fabry disease? Am J Cardiol 2010; 106:1492.</a></li><li><a class="nounderline abstract_t">Niemann M, Breunig F, Beer M, et al. The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy. Heart 2010; 96:1915.</a></li><li><a class="nounderline abstract_t">Kampmann C, Linhart A, Baehner F, et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 2008; 130:367.</a></li><li><a class="nounderline abstract_t">MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38:769.</a></li><li><a class="nounderline abstract_t">Wu JC, Ho CY, Skali H, et al. Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur Heart J 2010; 31:1088.</a></li><li><a class="nounderline abstract_t">Yousef Z, Elliott PM, Cecchi F, et al. Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. Eur Heart J 2013; 34:802.</a></li><li><a class="nounderline abstract_t">Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995; 333:288.</a></li><li><a class="nounderline abstract_t">Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002; 105:1407.</a></li><li><a class="nounderline abstract_t">Linhart A, Palecek T, Bultas J, et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J 2000; 139:1101.</a></li><li><a class="nounderline abstract_t">Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 2007; 93:528.</a></li><li><a class="nounderline abstract_t">Chimenti C, Padua L, Pazzaglia C, et al. Cardiac and skeletal myopathy in Fabry disease: a clinicopathologic correlative study. Hum Pathol 2012; 43:1444.</a></li><li><a class="nounderline abstract_t">Weidemann F, Strotmann JM, Niemann M, et al. Heart valve involvement in Fabry cardiomyopathy. Ultrasound Med Biol 2009; 35:730.</a></li><li><a class="nounderline abstract_t">Chimenti C, Morgante E, Tanzilli G, et al. Angina in fabry disease reflects coronary small vessel disease. Circ Heart Fail 2008; 1:161.</a></li><li><a class="nounderline abstract_t">Shah JS, Hughes DA, Sachdev B, et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 2005; 96:842.</a></li><li><a class="nounderline abstract_t">Ikari Y, Kuwako K, Yamaguchi T. Fabry's disease with complete atrioventricular block: histological evidence of involvement of the conduction system. Br Heart J 1992; 68:323.</a></li><li><a class="nounderline abstract_t">Mehta J, Tuna N, Moller JH, Desnick RJ. Electrocardiographic and vectorcardiographic abnormalities in Fabry's disease. Am Heart J 1977; 93:699.</a></li><li><a class="nounderline abstract_t">Pochis WT, Litzow JT, King BG, Kenny D. Electrophysiologic findings in Fabry's disease with a short PR interval. Am J Cardiol 1994; 74:203.</a></li><li><a class="nounderline abstract_t">Blum A, Ashkenazi H, Haromankov I, et al. First-degree atrioventricular block and restrictive physiology as cardiac manifestations of Fabry's disease. South Med J 2003; 96:212.</a></li><li><a class="nounderline abstract_t">Linhart A, Kampmann C, Zamorano JL, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 2007; 28:1228.</a></li><li><a class="nounderline abstract_t">Barbey F, Qanadli SD, Juli C, et al. Aortic remodelling in Fabry disease. Eur Heart J 2010; 31:347.</a></li><li><a class="nounderline abstract_t">Kampmann C, Wiethoff CM, Martin C, et al. Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathy. Acta Paediatr Suppl 2002; 91:21.</a></li><li><a class="nounderline abstract_t">Becker AE, Schoorl R, Balk AG, van der Heide RM. Cardiac manifestations of Fabry's disease. Report of a case with mitral insufficiency and electrocardiographic evidence of myocardial infarction. Am J Cardiol 1975; 36:829.</a></li><li><a class="nounderline abstract_t">Coats CJ, Parisi V, Ramos M, et al. Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with anderson-fabry disease. Am J Cardiol 2013; 111:111.</a></li><li><a class="nounderline abstract_t">Shanks M, Thompson RB, Paterson ID, et al. Systolic and diastolic function assessment in fabry disease patients using speckle-tracking imaging and comparison with conventional echocardiographic measurements. J Am Soc Echocardiogr 2013; 26:1407.</a></li><li><a class="nounderline abstract_t">Zamorano J, Serra V, Pérez de Isla L, et al. Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease. Eur J Echocardiogr 2011; 12:671.</a></li><li><a class="nounderline abstract_t">Pieroni M, Chimenti C, Ricci R, et al. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 2003; 107:1978.</a></li><li><a class="nounderline abstract_t">Krämer J, Niemann M, Liu D, et al. Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease. Eur Heart J 2013; 34:1587.</a></li><li><a class="nounderline abstract_t">Kawano M, Takenaka T, Otsuji Y, et al. Significance of asymmetric basal posterior wall thinning in patients with cardiac Fabry's disease. Am J Cardiol 2007; 99:261.</a></li><li><a class="nounderline abstract_t">Weidemann F, Breunig F, Beer M, et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 2005; 26:1221.</a></li><li><a class="nounderline abstract_t">Pieroni M, Chimenti C, De Cobelli F, et al. Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. J Am Coll Cardiol 2006; 47:1663.</a></li><li><a class="nounderline abstract_t">Kounas S, Demetrescu C, Pantazis AA, et al. The binary endocardial appearance is a poor discriminator of Anderson-Fabry disease from familial hypertrophic cardiomyopathy. J Am Coll Cardiol 2008; 51:2058.</a></li><li><a class="nounderline abstract_t">Koskenvuo JW, Engblom E, Kantola IM, et al. Echocardiography in Fabry disease: diagnostic value of endocardial border binary appearance. Clin Physiol Funct Imaging 2009; 29:177.</a></li><li><a class="nounderline abstract_t">Mundigler G, Gaggl M, Heinze G, et al. The endocardial binary appearance ('binary sign') is an unreliable marker for echocardiographic detection of Fabry disease in patients with left ventricular hypertrophy. Eur J Echocardiogr 2011; 12:744.</a></li><li><a class="nounderline abstract_t">Moon JC, Sheppard M, Reed E, et al. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson 2006; 8:479.</a></li><li><a class="nounderline abstract_t">De Cobelli F, Esposito A, Belloni E, et al. Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy. AJR Am J Roentgenol 2009; 192:W97.</a></li><li><a class="nounderline abstract_t">Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009; 119:524.</a></li><li><a class="nounderline abstract_t">Niemann M, Herrmann S, Hu K, et al. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging 2011; 4:592.</a></li><li><a class="nounderline abstract_t">Moon JC, Sachdev B, Elkington AG, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003; 24:2151.</a></li><li><a class="nounderline abstract_t">Elliott PM, Kindler H, Shah JS, et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 2006; 92:357.</a></li><li><a class="nounderline abstract_t">Weidemann F, Breunig F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003; 108:1299.</a></li><li><a class="nounderline abstract_t">Spinelli L, Pisani A, Sabbatini M, et al. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Genet 2004; 66:158.</a></li><li><a class="nounderline abstract_t">Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007; 146:77.</a></li><li><a class="nounderline abstract_t">Morita H, Larson MG, Barr SC, et al. Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study. Circulation 2006; 113:2697.</a></li><li><a class="nounderline abstract_t">Ommen SR, Nishimura RA, Edwards WD. Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy? Heart 2003; 89:929.</a></li><li><a class="nounderline abstract_t">Chimenti C, Pieroni M, Morgante E, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 2004; 110:1047.</a></li><li><a class="nounderline abstract_t">Namdar M, Steffel J, Vidovic M, et al. Electrocardiographic changes in early recognition of Fabry disease. Heart 2011; 97:485.</a></li><li><a class="nounderline abstract_t">Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline. J Card Fail 2009; 15:83.</a></li><li><a class="nounderline abstract_t">Maron MS, Xin W, Sims KB, et al. Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy. Am J Med 2018; 131:200.e1.</a></li><li><a class="nounderline abstract_t">Liu D, Hu K, Niemann M, et al. Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy. Circ Cardiovasc Imaging 2013; 6:1066.</a></li><li><a class="nounderline abstract_t">Thurberg BL, Fallon JT, Mitchell R, et al. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation 2009; 119:2561.</a></li><li><a class="nounderline abstract_t">Manohar VA, Moder KG, Edwards WD, Klarich K. Restrictive cardiomyopathy secondary to hydroxychloroquine therapy. J Rheumatol 2009; 36:440.</a></li><li><a class="nounderline abstract_t">Weidemann F, Maier SK, Störk S, et al. Usefulness of an Implantable Loop Recorder to Detect Clinically Relevant Arrhythmias in Patients With Advanced Fabry Cardiomyopathy. Am J Cardiol 2016; 118:264.</a></li><li><a class="nounderline abstract_t">WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128:e240.</a></li><li><a class="nounderline abstract_t">McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33:1787.</a></li><li><a class="nounderline abstract_t">Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16:e1.</a></li><li><a class="nounderline abstract_t">Cantor WJ, Daly P, Iwanochko M, et al. Cardiac transplantation for Fabry's disease. Can J Cardiol 1998; 14:81.</a></li></ol></div><div id="topicVersionRevision">Topic 4914 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12585833" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9100224" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17224688" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22049975" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Interdisciplinary approach towards female patients with Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12427421" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cardiac manifestations of Anderson-Fabry disease in heterozygous females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20109602" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Anderson-Fabry disease and the heart.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860841" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12068028" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cardiac involvement in Anderson-Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11694547" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21349401" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cardiovascular events in patients with fabry disease natural history data from the fabry registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21059442" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : When should cardiologists suspect Anderson-Fabry disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20965976" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18572264" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Onset and progression of the Anderson-Fabry disease related cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11732485" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20061327" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22736678" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7596372" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : An atypical variant of Fabry's disease in men with left ventricular hypertrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11914245" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10827394" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : New insights in cardiac structural changes in patients with Fabry's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17401074" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The heart in Anderson-Fabry disease and other lysosomal storage disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22406371" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cardiac and skeletal myopathy in Fabry disease: a clinicopathologic correlative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19110366" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Heart valve involvement in Fabry cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19808286" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Angina in fabry disease reflects coronary small vessel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16169374" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1389767" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Fabry's disease with complete atrioventricular block: histological evidence of involvement of the conduction system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/140598" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Electrocardiographic and vectorcardiographic abnormalities in Fabry's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8023796" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Electrophysiologic findings in Fabry's disease with a short PR interval.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12630653" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : First-degree atrioventricular block and restrictive physiology as cardiac manifestations of Fabry's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17483538" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19850557" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Aortic remodelling in Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12572838" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/812352" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cardiac manifestations of Fabry's disease. Report of a case with mitral insufficiency and electrocardiographic evidence of myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23040658" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with anderson-fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24125876" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Systolic and diastolic function assessment in fabry disease patients using speckle-tracking imaging and comparison with conventional echocardiographic measurements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21810826" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12668521" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Early detection of Fabry cardiomyopathy by tissue Doppler imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23520186" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17223430" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Significance of asymmetric basal posterior wall thinning in patients with cardiac Fabry's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728649" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16631007" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18498962" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The binary endocardial appearance is a poor discriminator of Anderson-Fabry disease from familial hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19320660" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Echocardiography in Fabry disease: diagnostic value of endocardial border binary appearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21857019" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The endocardial binary appearance ('binary sign') is an unreliable marker for echocardiographic detection of Fabry disease in patients with left ventricular hypertrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16755835" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19234246" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19153271" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21679893" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14643276" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16085718" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12952834" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15253767" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17179052" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16754800" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12860876" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15313943" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21270075" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Electrocardiographic changes in early recognition of Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19254666" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28943383" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24100046" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19414635" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19208570" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Restrictive cardiomyopathy secondary to hydroxychloroquine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27265676" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Usefulness of an Implantable Loop Recorder to Detect Clinically Relevant Arrhythmias in Patients With Advanced Fabry Cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23741058" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22611136" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20610207" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : HFSA 2010 Comprehensive Heart Failure Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9487277" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Cardiac transplantation for Fabry's disease.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
